Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 161   

Articles published

BMY 65.80 -0.20 (-0.30%)
price chart
Bristol-Myers Squibb Co (BMY) Hepatitis C Combo Succeeds In Trials
Bristol-Myers Squibb Co (NYSE:BMY) announced at the International Liver Congress on Saturday that the company's experimental hepatitis C combo proved to cure over 90% of patients when used in combination with Gilead Sciences, Inc.'s (NASDAQ:GILD) ...
CORRECTED-Bristol-Myers says hepatitis C drug combination succeeds in study  Reuters
Bristol-Myers Squibb Co (BMY) Rumored To Be Interested In Celgene Corporation
Word on the Street is that Bristol-Myers Squibb Co (NYSE:BMY) is interested in acquiring Celgene Corporation (NASDAQ:CELG).
Why A Bristol-Myers Squibb Bid On Celgene Is Plausible  Benzinga
Is Bristol-Myers Squibb. Co. About to Fall Apart?  Motley Fool
MMM Now #42 Largest Company, Surpassing Bristol-Myers Squibb
Market capitalization is an important data point for investors to keep an eye on, for various reasons. The most basic reason is that it gives a true comparison of the value attributed by the stock market to a given company's stock. Many beginning ...
CheckMate -057, a Pivotal Phase III Opdivo (nivolumab) Lung Cancer Trial ...  MarketWatch
Bristol-Myers Zigs While Market Zags  Wall Street Journal (blog)
June 5th Options Now Available For Bristol-Myers Squibb
Investors in Bristol-Myers Squibb Co. (Symbol: BMY) saw new options become available today, for the June 5th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the BMY options chain for the new June 5th contracts and ...
Bristol-Myers Squibb Company (BMY) Dip Doesn't Deter Option Bulls
Since hitting a 14-year high $69.20 on March 20, Bristol-Myers Squibb Co (NYSE:BMY) has dropped 7%, recently consolidating above its 60-day moving average.
Bristol-Myers Squibb Receives Average Rating of "Hold" from ...  Dakota Financial News
Morningstar Issues AA- Credit Rating to Bristol-Myers Squibb (BMY)  Mideast Time
Bristol-Myers Squibb Company (BMY) Strong In Pre-Market Trading
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
How Bristol-Myers Squibb (BMY) Makes its Money
As drug makers go, Bristol-Myers Squibb Co. (BMY) is acquisitive. Just in the last three years it's spent billions purchasing companies such as Amylin Pharmaceuticals and Flexus Biosciences, Inc., adding several valuable patents to an already extensive ...
General Report on Bristol-Myers Squibb Company (NYSE:BMY)  Street Report
High Outflow of Money Witnessed in Bristol-Myers Squibb Company  Trade Journo
BRIEF-EU medicines agency backs Bristol Myers Squibb's melanoma drug
Recommends approval of melanoma drug nivolumab from Bristol-Myers Squibb Co. * Recommends approval of tasimelteon for non 24-hour sleep-wake disorder from Vanda Pharmaceuticals Link to press release: (bit.
Surging Stocks - AVEO Pharmaceuticals, (NASDAQ:AVEO), Bristol-Myers ...
Bristol-Myers Squibb Company, declared positive results from a Phase II trial (CheckMate -069), evaluating the Opdivo (nivolumab)+Yervoy (ipilimumab) regimen as compared to Yervoy alone in patients with formerly untreated advanced melanoma.
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union ...
PRINCETON, N.J., Apr 24, 2015 (BUSINESS WIRE) -- Bristol-Myers Squibb Company BMY, -0.30% today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion ...
Bristol-Myers Squibb wins green light from European Medicines Agency to ...  The Westside Story